Edgar Snyder & Associates®
A Law Firm Representing Injured People
1-866-943-3427
Call Us Toll Free 24/7
Published on Dec 15, 2006 by Edgar Snyder

Merck’s Vioxx Replacement has Risks

Arcoxia

Critics claim that the study for a new drug that Merck intends to market in lieu of Vioxx is flawed. The drug was tested against an older pain killer known to raise heart risks, when a more logical study would have compared Arcoxia to a medicine that does not raise heart risks such as Naproxen, or Aleve.

Arcoxia belongs to the cox-2 class of drugs like Vioxx, which are meant to be gentler on the stomach, but includes other more serious risks. Critics say the new research raises “red flags” because studies indicated that Arcoxia did not have increased heart risks when compared to diclofenac, an older drug that has proven heart risks. A better study would have compared Arcoxia to a drug that did not raise heart risks to show its true side-effects.

It is suggested that those at risk of heart disease should stay away from cox-2 drugs and use a drug like naproxen. Those patients with ulcers or stomach bleeding should use cox-2 inhibitors.

Please note: All of our lawyers are licensed to practice in the state of Pennsylvania. We also have lawyers licensed to practice in Ohio, and West Virginia and we associate with experienced attorneys in other states. In addition, all drug-related litigation involves co-counsel.

“Doctors Not Sure About New Painkiller.” The Associated Press. November 13, 2006.
Think you have a case?
Think you have a case?
Free Case Review
First Name
Last Name
ZIP
Phone
Email
Briefly describe your injuries

Recent News

Sep 28, 2016
Pittsburgh Police Beefing Up DUI Patrols in 2017
Sep 26, 2016
Gear Up, Cool Down, and Stay Safe While Riding This Fall
Sep 16, 2016
Fall and Winter Car Kit
Sep 16, 2016
A New Law May Be Coming for Drivers
Sep 16, 2016
Smartphone Apps for Drivers
Tweet